Abstract Search

Abstract unavailable...

0 shares

ea0029p814 | Endocrine tumours and neoplasia | ICEECE2012

Efficacy of Everolimus to prevent hypoglycemia in patients with metastatic insulinomas: for the French group of endocrine tumors (GTE-Renaten)

Bernard V. , Lombard-Bohas C. , Goichot B. , Rohmer V. , Guimbaud R. , Niccoli P. , Chougnet C. , Ruszniewski P. , Baudin E.

Background: Refractory hypoglycemia in patients with metastatic insulinomas (RHMI) is an important cause of morbidity and mortality and everolimus could be a new therapeutic option.Methods: We conducted a restrospective multicentric study within the French group of endocrine tumors to evaluate the time to first symptomatic recurrence (TSR) in patients with RHMI after everolimus initiation. Ongoing hyperglycemic medical options and safety were recorded.</...

1 shares

ea0047oc8 | Spotlight on Neuroendocrine tumours | Theranostics2016

NETTER-1 Phase III in Patients with Midgut Neuroendocrine Tumors Treated with 177Lu-Dotatate: Efficacy, Safety, QoL Results and Subgroup Analysis

Strosberg Jonathan , Wolin E , Chasen B , Kulke M , Bushnell D , Caplin M , Baum R P , Kunz P , Hobday T , Hendifar A , Oberg K , Lopera Sierra M , Kwekkeboom D , Ruszniewski P , Krenning E

Background: Currently, there are limited therapeutic options for patients with advanced midgut neuroendocrine tumors progressing on first-line somatostatin analog therapy.Methods: NETTER-1 is the first phase III, randomized trial evaluating 177Lu-DOTA0-Tyr3-Octreotate (Lutathera®) in patients with progressive, somatostatin receptor positive midgut NETs. 230 patients were randomized to receive Lutathera 7.4...

0 shares

Endocrine Abstracts

Therapeutic management of GEP ET

Efficacy of Everolimus to prevent hypoglycemia in patients with metastatic insulinomas: for the French group of endocrine tumors (GTE-Renaten)

NETTER-1 Phase III in Patients with Midgut Neuroendocrine Tumors Treated with 177Lu-Dotatate: Efficacy, Safety, QoL Results and Subgroup Analysis

BiosciAbstracts